Media Thread, page-6712

Keytruda taught Merck how to build a blockbuster. But manufacturing a 2nd lightning bolt is easier said than done

Read the above article and what comes across is that, there is a failure galore in many trials, including a lot of combo trials that have come up short.

And when they do find anything worthwhile, gee, the success gets marred by the high toxicity outcome.

So, if anybody thinks IMU's B cell tech is anything to sneeze at, think again. So far, there has certainly been no toxicity or tolerability events. As for efficacy, it is no less than what is out there.

Due to the high failure rate and the desperate need to extend the life of the blockbuster Keytruda, imagine what would happen if the primary objective of the Hervaxx/Keytruda combo trial is achieved handsomely? Just think what would Merck do?!